CIA
PETX

Capital Impact Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Capital Impact Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,331
Closed -$184K – 322
2014
Q4 		$184K Hold
10,331
– – 0.09% 133
2014
Q3 		$104 Hold
10,331
– – ﹤0.01% 210
2014
Q2 		$161K Buy
+10,331
New +$146K 0.12% 167

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Impact Advisors's PETX Position: Q1 2015 in Review

Capital Impact Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2015, closing a stake of 10,331 shares — an estimated $184K sold.

Capital Impact Advisors first reported a position in PETX in Q2 2014 and held it in 3 quarters. The position peaked at $184K in Q4 2014. 93 funds tracked by Wall St. Rank hold PETX as of Q1 2015.

  • Capital Impact Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 10,331 Aratana Therapeutics, Inc. shares in Q1 2015, an estimated $184K.
  • Capital Impact Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's Aratana Therapeutics, Inc. position peaked at $184K in Q4 2014.
  • 93 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.